CRISPR Therapeutics AG (CRSP) Other financing activities (2017 - 2026)

CRISPR Therapeutics AG has disclosed Other financing activities across 10 years of filings, most recently posting $8.3 million for Q2 2026.

• In Q2 2026, Other financing activities rose 264.12% year-over-year to $8.3 million; the TTM figure through Jun 2026 stood at $38.0 million (up 284.05% YoY), while the FY2025 annual figure was $27.9 million, down 10.72% from the prior year.
• Other financing activities came in at $8.3 million for Q2 2026 at CRISPR Therapeutics AG, up from $6.2 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $25.2 million in Q1 2024 to a low of $546000.0 in Q2 2024.
• Average Other financing activities over 5 years is $7.8 million, with a median of $5.8 million recorded in 2023.
• Year-over-year, Other financing activities sank 96.74% in 2024 and soared 413.09% in 2025.
• Over 5 years, Other financing activities stood at $2.5 million in 2022, then soared by 150.93% to $6.2 million in 2023, then tumbled by 69.17% to $1.9 million in 2024, then soared by 156.81% to $4.9 million in 2025, then jumped by 68.64% to $8.3 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $8.3 million in Q2 2026, $6.2 million in Q1 2026, and $4.9 million in Q4 2025.